Pacira BioSciences, Inc.

Total Valuation

Pacira BioSciences, Inc. carries a market capitalization of 904.31M, placing it among publicly traded companies globally. Its enterprise value stands at 1.18B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Pacira BioSciences, Inc. currently has 39.31M shares outstanding.

Valuation Ratios

Pacira BioSciences, Inc. trades at a trailing price-to-earnings ratio of 189.63. The price-to-sales ratio is 1.33, and the price-to-book ratio stands at -4.96.

Enterprise Valuation

On an enterprise value basis, Pacira BioSciences, Inc. trades at an EV/EBITDA multiple of 11.04 and an EV/FCF ratio of 7.53. The EV/Sales ratio of 1.61 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 74.00 provides insight into valuation relative to core operating earnings.

Financial Position

Pacira BioSciences, Inc. maintains a current ratio of 4.73, meaning it holds 4.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 62.88, indicating elevated leverage, while an interest coverage ratio of 7.63 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Pacira BioSciences, Inc. has paid 8.03M in income taxes, reflecting an effective tax rate of 60.98.

Stock Price Statistics

Pacira BioSciences, Inc.'s stock has declined approximately -5.54643% over the past 52 weeks. The 50-day moving average sits at 23.64, while the 200-day moving average is 23.58.

Income Statement

Over the trailing twelve months, Pacira BioSciences, Inc. generated 734.86M in revenue and converted that into 5.14M in net income, yielding earnings per share of 0.12. EBITDA reached 107.18M, while operating income came in at 15.99M.

Balance Sheet

Pacira BioSciences, Inc. holds 202.18M in cash and equivalents against 411.18M in total debt, resulting in a net debt position of 223.35M. Total book value stands at -196.36M, with working capital of 406.17M providing operational flexibility.

Cash Flow

Pacira BioSciences, Inc. produced 142.22M in operating cash flow over the past twelve months. After subtracting -9.51M in capital expenditures, free cash flow totaled 132.71M - equivalent to 3.08 per share.

Margins

Pacira BioSciences, Inc. operates with a gross margin of 79.34, reflecting its pricing power and cost economics. The operating margin of 2.18 and net profit margin of 0.70 provide insight into operational efficiency.

Dividends & Yields

Scores

Pacira BioSciences, Inc. posts an Altman Z-Score of 2.25, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.